Inform Genomics Licenses Two US Patents from Taiwan's National Cheng Kung University to Advance Development of Precision Medicine Products
June 01, 2015 08:30 ET
|
Inform Genomics
Boston, MA, June 1, 2015 (GLOBE NEWSWIRE) -- Inform Genomics, Inc., a privately held company that utilizes a
proprietary analytic platform to develop genomic-based, precision
medicine products, and...
Inform Genomics Selects ICON as Contract Research Organization (CRO) for Pivotal Multicenter Study of HSCT/Mucositis Product Candidate
June 01, 2015 08:00 ET
|
Inform Genomics
Boston, MA, June 1, 2015 (GLOBE NEWSWIRE) -- Inform Genomics, Inc., a privately held company that utilizes a
proprietary analytic platform to develop genomic-based, precision
medicine products, today...
Inform Genomics Selects US Oncology Research as the Site Management Organization (SMO) for Pivotal Multicenter Study of OnPART
May 29, 2015 16:00 ET
|
Inform Genomics
Boston, MA, May 29, 2015 (GLOBE NEWSWIRE) -- Inform Genomics, Inc., a privately held company that utilizes a
proprietary analytic platform to discover and develop
genomic-based, precision medicine...
Inform Genomics Selects Vector Oncology as Contract Research Organization (CRO) for Pivotal Multicenter Study of OnPART
May 29, 2015 08:00 ET
|
Inform Genomics
Boston, MA and Memphis, TN, May 29, 2015 (GLOBE NEWSWIRE) -- Inform Genomics, Inc., a privately held company that utilizes a
proprietary analytic platform to develop genomic-based, precision
medicine...
Inform Genomics Announces Appointment of Carl de Moor, PhD, as Chief Technology Officer
July 28, 2014 08:00 ET
|
Inform Genomics
Boston, MA, July 28, 2014 (GLOBE NEWSWIRE) -- Inform
Genomics, Inc, a privately held company that utilizes a
proprietary technology platform to discover and develop
genomic-based, precision medicine...
INFORM GENOMICS and TESARO Enter Into Collaboration Agreement
October 15, 2013 07:00 ET
|
Inform Genomics
Boston, MA, Oct. 15, 2013 (GLOBE NEWSWIRE) -- Inform
Genomics, Inc., a private company focused on developing novel
platforms of genomic-based, personalized medicine products for
cancer supportive...